Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of hydroxysafflor yellow A in preparation of medicine for treating adenomyosis

A technology of adenomyosis and hydroxysafflower, applied in the field of biomedicine, can solve the problems of adenomyosis without hydroxysafflor yellow A, and achieve the effect of inhibiting collagen deposition and reducing the level

Pending Publication Date: 2022-07-29
NANJING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Hydroxysaffloryellow A (hydroxysaffloryellowA, HSYA) is the most effective water-soluble component of Compositae safflower pharmacological effects, can inhibit platelet aggregation and release induced by platelet activating factor, and can competitively inhibit platelet activating factor and platelet receptor The combination of safflower yellow is the active ingredient for promoting blood circulation and removing blood stasis. In the prior art, there have been reports on the anti-platelet and anti-myocardial ischemic effects, anti-oxidation, and anti-tumor activities of hydroxysafflower yellow A, but there is still no Introduction of Hydroxy-Free Safflower Yellow A in the Treatment of Adenomyosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydroxysafflor yellow A in preparation of medicine for treating adenomyosis
  • Application of hydroxysafflor yellow A in preparation of medicine for treating adenomyosis
  • Application of hydroxysafflor yellow A in preparation of medicine for treating adenomyosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Oral tamoxifen-induced adenomyosis model establishment:

[0022] 16 ICR mice (12 female mice, 4 male mice, 6 weeks old, body weight 18-20 g, provided by the animal room of Nanjing University School of Medicine) were caged in a male-female ratio of 1:3. Male mice were removed after conception of female mice. Newborn ICR mice were randomly divided into groups (model group n=45, control group n=10), and the mice were treated as follows on day 2-5 of birth: model group was instilled with 5 μL / g peanut oil / lecithin / condensed milk mixture ( 2: 0.2: 3, v / v / v) + 2.7 μmol / kg tamoxifen suspension, the control group was drip-fed with the same dose of vehicle mixture without drugs; From 22d onwards, the mice were separated from the females and allowed to eat and drink freely. All mice were housed in a clean-grade rat room with an air humidity of 50%-60%, a temperature of 21°C, and light / dark for 12 hours each. At the age of 42 days, the mice were randomly selected to be sacrific...

Embodiment 2

[0025] 16-week-old model mice (n=40) and blank control mice (Control, n=8) were selected, and the model mice were randomly divided into 5 groups: model group (Model), positive drug control group ( Celecoxib, celecoxib 6.5mg / kg), hydroxysafflor yellow low-dose group (HSYAL, 2.5mg / kg), hydroxysafflor yellow medium-dose group (HSYAM, 5mg / kg), hydroxysafflor yellow pigment The high-dose group (HSYAH, 10 mg / kg) was administered by intraperitoneal injection (ip). The model group and the blank control group were given the same amount of normal saline, administered daily for 3 weeks, and their body weight was measured weekly. After 3 weeks of administration, the mice were anesthetized with isoflurane, blood was collected from the retrobulbar venous plexus, centrifuged (5000g, 4°C, 15min), and the obtained mouse serum was stored at -80°C. Mice were sacrificed after blood collection, and the uterus was removed. The wet weight of the uterus was weighed, one side of the uterine horn was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of hydroxysafflor yellow A in preparation of a medicine for treating adenomyosis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, by taking tamoxifen-oral induced adenomyosis model mice as research objects, the treatment effect of the hydroxysafflor yellow A on the adenomyosis is found for the first time, and the hydroxysafflor yellow A can be used for relieving infiltration of endometrium and glands of the mice to muscular layers, collagen deposition, epithelial-mesenchymal transition and occurrence and development of fibrosis. The invention lays a pharmacological foundation for providing a new medicine for treating adenomyosis, and provides a new way for treating adenomyosis.

Description

technical field [0001] The invention relates to a new use of hydroxysafflor yellow A in preparing a medicine for treating adenomyosis, and belongs to the technical field of biomedicine. Background technique [0002] Adenomyosis is a common benign gynecological disease that invades the myometrium from the endometrial glands and interstitium downward, resulting in hemorrhage, hyperplasia of muscle fibers and connective tissue, and the formation of diffuse or localized lesions. The main clinical manifestations are dysmenorrhea, menorrhagia, abnormal uterine bleeding, chronic pelvic pain, low fertility and infertility. At present, there is no accurate clinical data in epidemiology, and the prevalence rate detected by hysterectomy is about 20%-30%. - 50-year-old multiparous, expanded to younger nulliparous women. There is still no effective treatment for adenomyosis. At present, the treatment methods are mainly surgical treatment and drug treatment. Drug treatment has many adve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/351A61P15/00
CPCA61K31/351A61P15/00Y02A50/30
Inventor 杜荣辉李欣然
Owner NANJING UNIV